Exact Sciences

EXAS

Market cap $19.7B

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. “In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests.

The Alger Mid Cap 40 ETF underperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Micron Technology, Inc. and MongoDB, Inc. were among the top contributors to performance. Roblox Corp., Nebius Group, and Robinhood Markets, Inc. were among the top detractors from performance.

We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterprise. We exited our successful investment in Exact Sciences Corporation after Abbott Laboratories announced it was acquiring the company for approximately $23 billion in cash.

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences' U.S. Patent No. 11,970,746 (the '746 patent) unpatentable. This decision follows the PTAB's July 2025 Final Written.